Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Bone Miner Res
Egile Nagusiak: Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2019
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916366/
https://ncbi.nlm.nih.gov/pubmed/31411768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3848
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak